Corcept Therapeutics
$116.23Change from previous close: +1.93%Absolute change: +$2.20
At a glance
- Revenue growth
- +12.79%
- 2025 vs 2024
- Net income growth
- −29.43%
- 2025 vs 2024
- Net margin
- 13.1%
- 2024: 20.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 761 | 675 | 482 | 402 | — |
| Cost of revenue | 13.0 | 10.9 | 6.5 | 5.4 | — |
| Gross profit | 748 | 664 | 476 | 396 | — |
| Selling, general and administrative | 449 | 280 | 184 | 153 | — |
| Research and development | 255 | 247 | 184 | 131 | — |
| Operating income | 44.8 | 137 | 107 | 113 | — |
| EBIT | 44.8 | 137 | 107 | 113 | — |
| EBITDA | 46.7 | 138 | 110 | 116 | — |
| Pre-tax income | 66.5 | 161 | 125 | 116 | — |
| Income tax | -33.2 | 20.3 | 18.4 | 14.8 | — |
| Net income | 99.7 | 141 | 106 | 101 | — |
| Net income to common shareholders | 98.2 | 140 | 105 | 101 | — |
| Basic EPS | 0.95 | 1.35 | 1.02 | 0.95 | — |
| Diluted EPS | 0.82 | 1.23 | 0.94 | 0.87 | — |
| Average shares (basic) | 104 | 103 | 104 | 107 | — |
| Average shares (diluted) | 120 | 113 | 112 | 116 | — |